nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Prednisolone—psoriatic arthritis	0.198	0.255	CbGbCtD
Nevirapine—CYP2A6—Dexamethasone—psoriatic arthritis	0.116	0.15	CbGbCtD
Nevirapine—CYP2B6—Dexamethasone—psoriatic arthritis	0.0758	0.0979	CbGbCtD
Nevirapine—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0616	0.0795	CbGbCtD
Nevirapine—CYP3A5—Dexamethasone—psoriatic arthritis	0.0597	0.0771	CbGbCtD
Nevirapine—CYP3A4—Triamcinolone—psoriatic arthritis	0.0467	0.0603	CbGbCtD
Nevirapine—CYP2C9—Dexamethasone—psoriatic arthritis	0.04	0.0517	CbGbCtD
Nevirapine—CYP3A4—Betamethasone—psoriatic arthritis	0.04	0.0517	CbGbCtD
Nevirapine—CYP3A4—Prednisolone—psoriatic arthritis	0.0395	0.051	CbGbCtD
Nevirapine—CYP3A4—Prednisone—psoriatic arthritis	0.0373	0.0482	CbGbCtD
Nevirapine—CYP2D6—Dexamethasone—psoriatic arthritis	0.0366	0.0473	CbGbCtD
Nevirapine—CYP3A4—Dexamethasone—psoriatic arthritis	0.0233	0.0301	CbGbCtD
Nevirapine—Ulcer—Prednisone—psoriatic arthritis	0.00116	0.00514	CcSEcCtD
Nevirapine—Diarrhoea—Auranofin—psoriatic arthritis	0.00116	0.00512	CcSEcCtD
Nevirapine—Dermatitis bullous—Prednisolone—psoriatic arthritis	0.00115	0.00508	CcSEcCtD
Nevirapine—Vomiting—Auranofin—psoriatic arthritis	0.00107	0.00476	CcSEcCtD
Nevirapine—Rash—Auranofin—psoriatic arthritis	0.00107	0.00472	CcSEcCtD
Nevirapine—Dermatitis—Auranofin—psoriatic arthritis	0.00106	0.00472	CcSEcCtD
Nevirapine—Dermatitis bullous—Triamcinolone—psoriatic arthritis	0.00105	0.00467	CcSEcCtD
Nevirapine—Skin exfoliation—Prednisone—psoriatic arthritis	0.00105	0.00464	CcSEcCtD
Nevirapine—Bone disorder—Methotrexate—psoriatic arthritis	0.00102	0.0045	CcSEcCtD
Nevirapine—Nausea—Auranofin—psoriatic arthritis	0.001	0.00445	CcSEcCtD
Nevirapine—Hepatic enzyme increased—Methotrexate—psoriatic arthritis	0.000969	0.0043	CcSEcCtD
Nevirapine—Ulcer—Methotrexate—psoriatic arthritis	0.000969	0.0043	CcSEcCtD
Nevirapine—Dermatitis bullous—Betamethasone—psoriatic arthritis	0.000957	0.00424	CcSEcCtD
Nevirapine—Dermatitis bullous—Dexamethasone—psoriatic arthritis	0.000957	0.00424	CcSEcCtD
Nevirapine—Inflammation—Methotrexate—psoriatic arthritis	0.000945	0.00419	CcSEcCtD
Nevirapine—Pancreatitis—Prednisolone—psoriatic arthritis	0.000929	0.00412	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.000887	0.00393	CcSEcCtD
Nevirapine—Skin exfoliation—Methotrexate—psoriatic arthritis	0.000875	0.00388	CcSEcCtD
Nevirapine—Pancreatitis—Triamcinolone—psoriatic arthritis	0.000854	0.00378	CcSEcCtD
Nevirapine—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.000852	0.00378	CcSEcCtD
Nevirapine—Mouth ulceration—Methotrexate—psoriatic arthritis	0.000829	0.00367	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisolone—psoriatic arthritis	0.000828	0.00367	CcSEcCtD
Nevirapine—Conjunctivitis—Prednisolone—psoriatic arthritis	0.000821	0.00364	CcSEcCtD
Nevirapine—Lymphadenopathy—Methotrexate—psoriatic arthritis	0.00078	0.00346	CcSEcCtD
Nevirapine—Face oedema—Prednisone—psoriatic arthritis	0.000769	0.00341	CcSEcCtD
Nevirapine—Neuropathy peripheral—Triamcinolone—psoriatic arthritis	0.000761	0.00337	CcSEcCtD
Nevirapine—Neuropathy peripheral—Methylprednisolone—psoriatic arthritis	0.00076	0.00337	CcSEcCtD
Nevirapine—Conjunctivitis—Triamcinolone—psoriatic arthritis	0.000755	0.00335	CcSEcCtD
Nevirapine—Hepatic failure—Methotrexate—psoriatic arthritis	0.000741	0.00328	CcSEcCtD
Nevirapine—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.000713	0.00316	CcSEcCtD
Nevirapine—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.000713	0.00316	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Methotrexate—psoriatic arthritis	0.000705	0.00313	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000702	0.00311	CcSEcCtD
Nevirapine—Neuropathy peripheral—Betamethasone—psoriatic arthritis	0.000691	0.00306	CcSEcCtD
Nevirapine—Neuropathy peripheral—Dexamethasone—psoriatic arthritis	0.000691	0.00306	CcSEcCtD
Nevirapine—Conjunctivitis—Betamethasone—psoriatic arthritis	0.000685	0.00304	CcSEcCtD
Nevirapine—Conjunctivitis—Dexamethasone—psoriatic arthritis	0.000685	0.00304	CcSEcCtD
Nevirapine—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.000684	0.00303	CcSEcCtD
Nevirapine—Pancreatitis—Prednisone—psoriatic arthritis	0.000675	0.00299	CcSEcCtD
Nevirapine—Erythema—Prednisolone—psoriatic arthritis	0.00066	0.00292	CcSEcCtD
Nevirapine—Neutropenia—Prednisone—psoriatic arthritis	0.000644	0.00285	CcSEcCtD
Nevirapine—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.000628	0.00278	CcSEcCtD
Nevirapine—Hyperglycaemia—Prednisone—psoriatic arthritis	0.000621	0.00275	CcSEcCtD
Nevirapine—Liver function test abnormal—Methotrexate—psoriatic arthritis	0.000614	0.00272	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisolone—psoriatic arthritis	0.000612	0.00271	CcSEcCtD
Nevirapine—Erythema—Triamcinolone—psoriatic arthritis	0.000607	0.00269	CcSEcCtD
Nevirapine—Erythema—Methylprednisolone—psoriatic arthritis	0.000606	0.00268	CcSEcCtD
Nevirapine—Angioedema—Prednisolone—psoriatic arthritis	0.000603	0.00267	CcSEcCtD
Nevirapine—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000602	0.00267	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000599	0.00266	CcSEcCtD
Nevirapine—Malaise—Prednisolone—psoriatic arthritis	0.000595	0.00264	CcSEcCtD
Nevirapine—Eosinophilia—Methotrexate—psoriatic arthritis	0.000569	0.00252	CcSEcCtD
Nevirapine—Pancreatitis—Methotrexate—psoriatic arthritis	0.000564	0.0025	CcSEcCtD
Nevirapine—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.000563	0.0025	CcSEcCtD
Nevirapine—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.000562	0.00249	CcSEcCtD
Nevirapine—Discomfort—Prednisolone—psoriatic arthritis	0.000555	0.00246	CcSEcCtD
Nevirapine—Angioedema—Triamcinolone—psoriatic arthritis	0.000555	0.00246	CcSEcCtD
Nevirapine—Angioedema—Methylprednisolone—psoriatic arthritis	0.000553	0.00245	CcSEcCtD
Nevirapine—Erythema—Betamethasone—psoriatic arthritis	0.000551	0.00244	CcSEcCtD
Nevirapine—Erythema—Dexamethasone—psoriatic arthritis	0.000551	0.00244	CcSEcCtD
Nevirapine—Malaise—Triamcinolone—psoriatic arthritis	0.000547	0.00243	CcSEcCtD
Nevirapine—Malaise—Methylprednisolone—psoriatic arthritis	0.000546	0.00242	CcSEcCtD
Nevirapine—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000541	0.0024	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000539	0.00239	CcSEcCtD
Nevirapine—Oedema—Prednisolone—psoriatic arthritis	0.000539	0.00239	CcSEcCtD
Nevirapine—Neutropenia—Methotrexate—psoriatic arthritis	0.000538	0.00238	CcSEcCtD
Nevirapine—Myalgia—Triamcinolone—psoriatic arthritis	0.000517	0.00229	CcSEcCtD
Nevirapine—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000516	0.00228	CcSEcCtD
Nevirapine—Myalgia—Methylprednisolone—psoriatic arthritis	0.000516	0.00228	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000512	0.00227	CcSEcCtD
Nevirapine—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000511	0.00226	CcSEcCtD
Nevirapine—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000511	0.00226	CcSEcCtD
Nevirapine—Discomfort—Triamcinolone—psoriatic arthritis	0.00051	0.00226	CcSEcCtD
Nevirapine—Discomfort—Methylprednisolone—psoriatic arthritis	0.000509	0.00226	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000508	0.00225	CcSEcCtD
Nevirapine—Renal failure—Methotrexate—psoriatic arthritis	0.000504	0.00223	CcSEcCtD
Nevirapine—Angioedema—Dexamethasone—psoriatic arthritis	0.000503	0.00223	CcSEcCtD
Nevirapine—Angioedema—Betamethasone—psoriatic arthritis	0.000503	0.00223	CcSEcCtD
Nevirapine—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000499	0.00221	CcSEcCtD
Nevirapine—Immune system disorder—Prednisone—psoriatic arthritis	0.000498	0.00221	CcSEcCtD
Nevirapine—Malaise—Dexamethasone—psoriatic arthritis	0.000497	0.0022	CcSEcCtD
Nevirapine—Malaise—Betamethasone—psoriatic arthritis	0.000497	0.0022	CcSEcCtD
Nevirapine—Oedema—Triamcinolone—psoriatic arthritis	0.000495	0.00219	CcSEcCtD
Nevirapine—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000495	0.00219	CcSEcCtD
Nevirapine—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000494	0.00219	CcSEcCtD
Nevirapine—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000485	0.00215	CcSEcCtD
Nevirapine—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000485	0.00215	CcSEcCtD
Nevirapine—Paraesthesia—Prednisolone—psoriatic arthritis	0.000484	0.00214	CcSEcCtD
Nevirapine—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00048	0.00213	CcSEcCtD
Nevirapine—Erythema—Prednisone—psoriatic arthritis	0.00048	0.00213	CcSEcCtD
Nevirapine—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000479	0.00212	CcSEcCtD
Nevirapine—Myalgia—Dexamethasone—psoriatic arthritis	0.000469	0.00208	CcSEcCtD
Nevirapine—Myalgia—Betamethasone—psoriatic arthritis	0.000469	0.00208	CcSEcCtD
Nevirapine—Discomfort—Dexamethasone—psoriatic arthritis	0.000463	0.00205	CcSEcCtD
Nevirapine—Discomfort—Betamethasone—psoriatic arthritis	0.000463	0.00205	CcSEcCtD
Nevirapine—Pain—Prednisolone—psoriatic arthritis	0.000461	0.00204	CcSEcCtD
Nevirapine—Hepatitis—Methotrexate—psoriatic arthritis	0.00046	0.00204	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000451	0.002	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00045	0.002	CcSEcCtD
Nevirapine—Oedema—Betamethasone—psoriatic arthritis	0.000449	0.00199	CcSEcCtD
Nevirapine—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000449	0.00199	CcSEcCtD
Nevirapine—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000449	0.00199	CcSEcCtD
Nevirapine—Oedema—Dexamethasone—psoriatic arthritis	0.000449	0.00199	CcSEcCtD
Nevirapine—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000445	0.00197	CcSEcCtD
Nevirapine—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000445	0.00197	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000444	0.00197	CcSEcCtD
Nevirapine—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000444	0.00197	CcSEcCtD
Nevirapine—Anaemia—Prednisone—psoriatic arthritis	0.000443	0.00196	CcSEcCtD
Nevirapine—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000441	0.00195	CcSEcCtD
Nevirapine—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000441	0.00195	CcSEcCtD
Nevirapine—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00044	0.00195	CcSEcCtD
Nevirapine—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00044	0.00195	CcSEcCtD
Nevirapine—Angioedema—Prednisone—psoriatic arthritis	0.000438	0.00194	CcSEcCtD
Nevirapine—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000435	0.00193	CcSEcCtD
Nevirapine—Malaise—Prednisone—psoriatic arthritis	0.000432	0.00192	CcSEcCtD
Nevirapine—Anorexia—Betamethasone—psoriatic arthritis	0.000428	0.0019	CcSEcCtD
Nevirapine—Anorexia—Dexamethasone—psoriatic arthritis	0.000428	0.0019	CcSEcCtD
Nevirapine—Urticaria—Prednisolone—psoriatic arthritis	0.000428	0.0019	CcSEcCtD
Nevirapine—Fatigue—Triamcinolone—psoriatic arthritis	0.000427	0.00189	CcSEcCtD
Nevirapine—Fatigue—Methylprednisolone—psoriatic arthritis	0.000426	0.00189	CcSEcCtD
Nevirapine—Pain—Triamcinolone—psoriatic arthritis	0.000424	0.00188	CcSEcCtD
Nevirapine—Immune system disorder—Methotrexate—psoriatic arthritis	0.000416	0.00184	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000409	0.00181	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000409	0.00181	CcSEcCtD
Nevirapine—Arthralgia—Prednisone—psoriatic arthritis	0.000408	0.00181	CcSEcCtD
Nevirapine—Myalgia—Prednisone—psoriatic arthritis	0.000408	0.00181	CcSEcCtD
Nevirapine—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000408	0.00181	CcSEcCtD
Nevirapine—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000407	0.0018	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000405	0.0018	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000404	0.00179	CcSEcCtD
Nevirapine—Paraesthesia—Betamethasone—psoriatic arthritis	0.000404	0.00179	CcSEcCtD
Nevirapine—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000404	0.00179	CcSEcCtD
Nevirapine—Discomfort—Prednisone—psoriatic arthritis	0.000403	0.00179	CcSEcCtD
Nevirapine—Erythema—Methotrexate—psoriatic arthritis	0.000401	0.00178	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000397	0.00176	CcSEcCtD
Nevirapine—Urticaria—Triamcinolone—psoriatic arthritis	0.000393	0.00174	CcSEcCtD
Nevirapine—Urticaria—Methylprednisolone—psoriatic arthritis	0.000393	0.00174	CcSEcCtD
Nevirapine—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000392	0.00174	CcSEcCtD
Nevirapine—Oedema—Prednisone—psoriatic arthritis	0.000391	0.00173	CcSEcCtD
Nevirapine—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000391	0.00173	CcSEcCtD
Nevirapine—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000391	0.00173	CcSEcCtD
Nevirapine—Decreased appetite—Betamethasone—psoriatic arthritis	0.000391	0.00173	CcSEcCtD
Nevirapine—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000391	0.00173	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000388	0.00172	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000388	0.00172	CcSEcCtD
Nevirapine—Fatigue—Dexamethasone—psoriatic arthritis	0.000387	0.00172	CcSEcCtD
Nevirapine—Fatigue—Betamethasone—psoriatic arthritis	0.000387	0.00172	CcSEcCtD
Nevirapine—Pain—Betamethasone—psoriatic arthritis	0.000384	0.0017	CcSEcCtD
Nevirapine—Pain—Dexamethasone—psoriatic arthritis	0.000384	0.0017	CcSEcCtD
Nevirapine—Nervous system disorder—Prednisone—psoriatic arthritis	0.000384	0.0017	CcSEcCtD
Nevirapine—Skin disorder—Prednisone—psoriatic arthritis	0.00038	0.00168	CcSEcCtD
Nevirapine—Anorexia—Prednisone—psoriatic arthritis	0.000373	0.00165	CcSEcCtD
Nevirapine—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000372	0.00165	CcSEcCtD
Nevirapine—Anaemia—Methotrexate—psoriatic arthritis	0.00037	0.00164	CcSEcCtD
Nevirapine—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00037	0.00164	CcSEcCtD
Nevirapine—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00037	0.00164	CcSEcCtD
Nevirapine—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000367	0.00163	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000367	0.00163	CcSEcCtD
Nevirapine—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000365	0.00162	CcSEcCtD
Nevirapine—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000364	0.00161	CcSEcCtD
Nevirapine—Malaise—Methotrexate—psoriatic arthritis	0.000361	0.0016	CcSEcCtD
Nevirapine—Urticaria—Betamethasone—psoriatic arthritis	0.000357	0.00158	CcSEcCtD
Nevirapine—Urticaria—Dexamethasone—psoriatic arthritis	0.000357	0.00158	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000357	0.00158	CcSEcCtD
Nevirapine—Asthenia—Triamcinolone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Body temperature increased—Betamethasone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Abdominal pain—Betamethasone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Asthenia—Methylprednisolone—psoriatic arthritis	0.000355	0.00157	CcSEcCtD
Nevirapine—Paraesthesia—Prednisone—psoriatic arthritis	0.000351	0.00156	CcSEcCtD
Nevirapine—Pruritus—Triamcinolone—psoriatic arthritis	0.00035	0.00155	CcSEcCtD
Nevirapine—Pruritus—Methylprednisolone—psoriatic arthritis	0.00035	0.00155	CcSEcCtD
Nevirapine—Arthralgia—Methotrexate—psoriatic arthritis	0.000341	0.00151	CcSEcCtD
Nevirapine—Myalgia—Methotrexate—psoriatic arthritis	0.000341	0.00151	CcSEcCtD
Nevirapine—Decreased appetite—Prednisone—psoriatic arthritis	0.00034	0.00151	CcSEcCtD
Nevirapine—Rash—Prednisolone—psoriatic arthritis	0.00034	0.0015	CcSEcCtD
Nevirapine—Dermatitis—Prednisolone—psoriatic arthritis	0.000339	0.0015	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000339	0.0015	CcSEcCtD
Nevirapine—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000338	0.0015	CcSEcCtD
Nevirapine—Fatigue—Prednisone—psoriatic arthritis	0.000337	0.0015	CcSEcCtD
Nevirapine—Headache—Prednisolone—psoriatic arthritis	0.000337	0.0015	CcSEcCtD
Nevirapine—Discomfort—Methotrexate—psoriatic arthritis	0.000337	0.00149	CcSEcCtD
Nevirapine—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000327	0.00145	CcSEcCtD
Nevirapine—Feeling abnormal—Prednisone—psoriatic arthritis	0.000323	0.00143	CcSEcCtD
Nevirapine—Asthenia—Betamethasone—psoriatic arthritis	0.000322	0.00143	CcSEcCtD
Nevirapine—Asthenia—Dexamethasone—psoriatic arthritis	0.000322	0.00143	CcSEcCtD
Nevirapine—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000321	0.00142	CcSEcCtD
Nevirapine—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00032	0.00142	CcSEcCtD
Nevirapine—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00032	0.00142	CcSEcCtD
Nevirapine—Nausea—Prednisolone—psoriatic arthritis	0.00032	0.00142	CcSEcCtD
Nevirapine—Pruritus—Betamethasone—psoriatic arthritis	0.000318	0.00141	CcSEcCtD
Nevirapine—Pruritus—Dexamethasone—psoriatic arthritis	0.000318	0.00141	CcSEcCtD
Nevirapine—Skin disorder—Methotrexate—psoriatic arthritis	0.000318	0.00141	CcSEcCtD
Nevirapine—Vomiting—Triamcinolone—psoriatic arthritis	0.000315	0.0014	CcSEcCtD
Nevirapine—Vomiting—Methylprednisolone—psoriatic arthritis	0.000314	0.00139	CcSEcCtD
Nevirapine—Rash—Triamcinolone—psoriatic arthritis	0.000312	0.00138	CcSEcCtD
Nevirapine—Dermatitis—Triamcinolone—psoriatic arthritis	0.000312	0.00138	CcSEcCtD
Nevirapine—Anorexia—Methotrexate—psoriatic arthritis	0.000312	0.00138	CcSEcCtD
Nevirapine—Rash—Methylprednisolone—psoriatic arthritis	0.000312	0.00138	CcSEcCtD
Nevirapine—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000311	0.00138	CcSEcCtD
Nevirapine—Urticaria—Prednisone—psoriatic arthritis	0.000311	0.00138	CcSEcCtD
Nevirapine—Headache—Triamcinolone—psoriatic arthritis	0.00031	0.00138	CcSEcCtD
Nevirapine—Headache—Methylprednisolone—psoriatic arthritis	0.00031	0.00137	CcSEcCtD
Nevirapine—Abdominal pain—Prednisone—psoriatic arthritis	0.000309	0.00137	CcSEcCtD
Nevirapine—Body temperature increased—Prednisone—psoriatic arthritis	0.000309	0.00137	CcSEcCtD
Nevirapine—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000307	0.00136	CcSEcCtD
Nevirapine—Diarrhoea—Betamethasone—psoriatic arthritis	0.000307	0.00136	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000298	0.00132	CcSEcCtD
Nevirapine—Nausea—Triamcinolone—psoriatic arthritis	0.000294	0.0013	CcSEcCtD
Nevirapine—Paraesthesia—Methotrexate—psoriatic arthritis	0.000294	0.0013	CcSEcCtD
Nevirapine—Nausea—Methylprednisolone—psoriatic arthritis	0.000294	0.0013	CcSEcCtD
Nevirapine—Somnolence—Methotrexate—psoriatic arthritis	0.000291	0.00129	CcSEcCtD
Nevirapine—Hypersensitivity—Prednisone—psoriatic arthritis	0.000288	0.00128	CcSEcCtD
Nevirapine—Vomiting—Betamethasone—psoriatic arthritis	0.000286	0.00127	CcSEcCtD
Nevirapine—Vomiting—Dexamethasone—psoriatic arthritis	0.000286	0.00127	CcSEcCtD
Nevirapine—Decreased appetite—Methotrexate—psoriatic arthritis	0.000284	0.00126	CcSEcCtD
Nevirapine—Rash—Betamethasone—psoriatic arthritis	0.000283	0.00126	CcSEcCtD
Nevirapine—Rash—Dexamethasone—psoriatic arthritis	0.000283	0.00126	CcSEcCtD
Nevirapine—Dermatitis—Dexamethasone—psoriatic arthritis	0.000283	0.00125	CcSEcCtD
Nevirapine—Dermatitis—Betamethasone—psoriatic arthritis	0.000283	0.00125	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000282	0.00125	CcSEcCtD
Nevirapine—Fatigue—Methotrexate—psoriatic arthritis	0.000282	0.00125	CcSEcCtD
Nevirapine—Headache—Dexamethasone—psoriatic arthritis	0.000282	0.00125	CcSEcCtD
Nevirapine—Headache—Betamethasone—psoriatic arthritis	0.000282	0.00125	CcSEcCtD
Nevirapine—Asthenia—Prednisone—psoriatic arthritis	0.000281	0.00124	CcSEcCtD
Nevirapine—Pain—Methotrexate—psoriatic arthritis	0.00028	0.00124	CcSEcCtD
Nevirapine—Pruritus—Prednisone—psoriatic arthritis	0.000277	0.00123	CcSEcCtD
Nevirapine—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00027	0.00119	CcSEcCtD
Nevirapine—Diarrhoea—Prednisone—psoriatic arthritis	0.000268	0.00119	CcSEcCtD
Nevirapine—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000267	0.00119	CcSEcCtD
Nevirapine—Nausea—Dexamethasone—psoriatic arthritis	0.000267	0.00118	CcSEcCtD
Nevirapine—Nausea—Betamethasone—psoriatic arthritis	0.000267	0.00118	CcSEcCtD
Nevirapine—Urticaria—Methotrexate—psoriatic arthritis	0.00026	0.00115	CcSEcCtD
Nevirapine—Abdominal pain—Methotrexate—psoriatic arthritis	0.000259	0.00115	CcSEcCtD
Nevirapine—Body temperature increased—Methotrexate—psoriatic arthritis	0.000259	0.00115	CcSEcCtD
Nevirapine—Vomiting—Prednisone—psoriatic arthritis	0.000249	0.0011	CcSEcCtD
Nevirapine—Rash—Prednisone—psoriatic arthritis	0.000247	0.00109	CcSEcCtD
Nevirapine—Dermatitis—Prednisone—psoriatic arthritis	0.000247	0.00109	CcSEcCtD
Nevirapine—Headache—Prednisone—psoriatic arthritis	0.000245	0.00109	CcSEcCtD
Nevirapine—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000241	0.00107	CcSEcCtD
Nevirapine—Asthenia—Methotrexate—psoriatic arthritis	0.000235	0.00104	CcSEcCtD
Nevirapine—Nausea—Prednisone—psoriatic arthritis	0.000232	0.00103	CcSEcCtD
Nevirapine—Pruritus—Methotrexate—psoriatic arthritis	0.000231	0.00103	CcSEcCtD
Nevirapine—Diarrhoea—Methotrexate—psoriatic arthritis	0.000224	0.000992	CcSEcCtD
Nevirapine—Vomiting—Methotrexate—psoriatic arthritis	0.000208	0.000922	CcSEcCtD
Nevirapine—Rash—Methotrexate—psoriatic arthritis	0.000206	0.000914	CcSEcCtD
Nevirapine—Dermatitis—Methotrexate—psoriatic arthritis	0.000206	0.000913	CcSEcCtD
Nevirapine—Headache—Methotrexate—psoriatic arthritis	0.000205	0.000908	CcSEcCtD
Nevirapine—Nausea—Methotrexate—psoriatic arthritis	0.000194	0.000861	CcSEcCtD
